AI Verdict
JOE has stronger fundamentals based on our AI analysis.
JSPRW vs JOE Fundamental Comparison
| Metric | JSPRW | JOE |
|---|---|---|
| Revenue | $-246,000.0 | $513.2M |
| Net Income | $-75.8M | $115.6M |
| Net Margin | 30,813.4% | 22.5% |
| ROE | -1,826.1% | 15.1% |
| ROA | -211.9% | 7.6% |
| Current Ratio | 2.62x | N/A |
| Debt/Equity | 0.00x | 0.51x |
| EPS | $-3.95 | $1.99 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
JSPRW vs JOE: Frequently Asked Questions
Is JSPRW or JOE a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), JOE has stronger fundamentals. JSPRW is rated STRONG SELL (85% confidence) while JOE is rated BUY (74% confidence). This is not investment advice.
How does JSPRW compare to JOE fundamentally?
Jasper Therapeutics, Inc. has ROE of -1,826.1% vs ST JOE Co's 15.1%. Net margins are 30,813.4% vs 22.5% respectively.
Which stock pays higher dividends, JSPRW or JOE?
JSPRW has a dividend yield of N/A or no dividend while JOE has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in JSPRW or JOE for long term?
For long-term investing, consider that JSPRW has STRONG SELL rating with 85% confidence, while JOE has BUY rating with 74% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about JSPRW vs JOE?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For JSPRW vs JOE, the AI consensus favors JOE based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.